Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 160
Filtrar
1.
Eur J Clin Nutr ; 77(7): 757-760, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-36859659

RESUMO

Thiamine deficiency, commonly presenting as dry and wet beriberi, a lesser-known entity in the present era, is increasingly being reported from Kashmir, a north Indian state. The present study aims to present the clinical profile of patients presenting with high-output heart failure (HOHF). Subjects with a primary diagnosis of denovo heart failure and features suggestive of HOHF were recruited; those who responded to intravenous administration of thiamine alone (responders) were adults with no co-morbidities and those who required other medications particularly diuretics (non-responders) were elderly with co-morbidities and underlying heart disease. Responders showed considerably lower mean thiamine pyrophosphate (TPP) levels and higher mean lactate and venous oxygen saturation than non-responders. More importantly, the mean drop in lactate and SVO2 following thiamine therapy was more in responders. In a setting of high risk for thiamine deficiency, features suggestive of HOHF along with elevated lactate and higher venous oxygen saturation, a response to thiamine challenge may serve as surrogate marker of thiamine deficiency.


Assuntos
Beriberi , Insuficiência Cardíaca , Deficiência de Tiamina , Humanos , Adulto , Idoso , Tiamina/uso terapêutico , Deficiência de Tiamina/tratamento farmacológico , Beriberi/tratamento farmacológico , Beriberi/diagnóstico , Insuficiência Cardíaca/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico
2.
BMC Pharmacol Toxicol ; 20(1): 40, 2019 07 05.
Artigo em Inglês | MEDLINE | ID: mdl-31277705

RESUMO

BACKGROUND: We aimed to determine the protective effects of thiamine pyrophosphate on ethanol induced optic neuropathy in an experimental model. METHODS: The rats were assigned into 4 groups, with 6 rats in each group as follows: healthy controls (HC group), only ethanol administered group (EtOH group), ethanol + thiamine pyrophosphate (20 mg/kg) administered group (TEt-20 group), and only thiamine pyrophosphate (20 mg/kg) (TPG group) administered group. To the rats in TEt-20 and TPG groups, 20 mg/kg thiamine pyrophosphate was administered via intraperitoneal route. To the rats in HC and EtOH groups, the same volume (0.5 ml) of distilled water as solvent was applied in the same manner. To the rats in TEt-20 and EtOH groups, one hour after application of thiamine pyrophosphate or distilled water, 32% ethanol with a dose of 5 g/kg was administered via oral gavage. This procedure was repeated once a day for 6 weeks. From the blood samples and tissues obtained from the rats, Malondialdehyde (MDA), reduced glutathione (GSH), interleukin 1 beta (IL-1ß) and tumor necrosis factor alpha (TNF-α) levels were studied. Histopathological evaluations were performed to the optic nerve tissue. RESULTS: Serum and tissue IL-1ß, TNF-α and MDA levels were the highest in EtOH group which were significantly lower in thiamine pyrophosphate administered group (TEt-20 group) (p: 0.001). Serum and tissue reduced GSH levels were the lowest in EtOH group which were also significantly higher in TEt-20 group (p:0.001). In histopathological evaluations, in EtOH group there was obvious destruction and edema with hemorrhage and dilated blood vessels which were not present in any other groups. CONCLUSIONS: There was an apparent destruction in ethanol administered group in histopathological analyses with an augmented level of oxidative stress markers and all those alterations were prevented with concomitant thiamine pyrophosphate administration. These protective effects of thiamine pyrophosphate are extremely important in chronic ethanol consumption. Clinical studies are warranted to define the exact role of thiamine pyrophosphate in prevention of ethanol induced optic neuropathy.


Assuntos
Etanol/toxicidade , Traumatismos do Nervo Óptico/induzido quimicamente , Traumatismos do Nervo Óptico/tratamento farmacológico , Substâncias Protetoras/uso terapêutico , Tiamina Pirofosfato/uso terapêutico , Animais , Glutationa/metabolismo , Interleucina-1beta/metabolismo , Masculino , Malondialdeído/metabolismo , Nervo Óptico/efeitos dos fármacos , Nervo Óptico/metabolismo , Nervo Óptico/patologia , Traumatismos do Nervo Óptico/metabolismo , Substâncias Protetoras/farmacologia , Ratos Wistar , Tiamina Pirofosfato/farmacologia , Fator de Necrose Tumoral alfa/metabolismo
3.
Artigo em Russo | MEDLINE | ID: mdl-29460903

RESUMO

AIM: To study the efficacy of the complex therapy, including cocarnit (group B vitamins, triphosadenine and nicotinamide), of diabetic neuropathy. MATERIAL AND METHODS: Forty-one patients with diabetes mellitus type 2 and distal symmetric sensorimotor polyneuropathy were examined. Patients were divided into 2 groups. Patients of the main group (n=26) received complex therapy, including cocarnit, and patients of the comparison group (n=15) received standard treatment. RESULTS AND CONCLUSION: The positive dynamics based on the VAS (р=0.0001), TSS (р=0.0001), NSS (р=0.001), NDS (р=0.0431), SF-36 (р=0.0008), electroneuromyographic results and glycated hemoglobin levels was observed in the main group. In patients of the comparison group, the positive dynamics was instable; the scores of clinical scales did not reach statistical significance. The results suggest the use of cocarnit in the complex treatment of patients with diabetic neuropathy.


Assuntos
Trifosfato de Adenosina/uso terapêutico , Diabetes Mellitus Tipo 2/complicações , Neuropatias Diabéticas/tratamento farmacológico , Neuropatias Diabéticas/etiologia , Niacinamida/uso terapêutico , Tiamina Pirofosfato/uso terapêutico , Vitamina B 12/uso terapêutico , Complexo Vitamínico B/uso terapêutico , Neuropatias Diabéticas/fisiopatologia , Combinação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Escala Visual Analógica
4.
Acta Cir Bras ; 31(3): 168-75, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27050787

RESUMO

PURPOSE: To investigate the effects of thiamine pyrophosphate (TPP) against desflurane induced hepatotoxicity. METHODS: Thirty experimental animals were divided into groups as healthy (HG), desflurane control (DCG) , TPP and desflurane group (TDG). 20 mg/kg TPP was injected to intraperitoneally TDG. After one hour of TPP administration, desflurane was applied for two hours. After 24 hours, liver tissues of the animals killed with decapitation were removed. The oxidant/antioxidant levels and ALT, AST and LDH activities were measured. The histopathological examinations were performed in the liver tissues for all rats. RESULTS: Notwithstanding the levels of oxidants and liver enzymes were significantly increased (p<0.0001), antioxidant levels were significantly decreased in DCG (p<0.0001). On contrary to the antioxidant parameters were increased (p<0.05) the oxidant parameters and liver enzymes were decreased in TDG (p<0.0001). Whereas multiple prominent, congestion, hemorrhage and dilatation were observed in sinusoids and lymphocyte-rich inflammation results in the centrilobular and portal areas of liver tissue in DCG, these findings were observed less frequently in TDG. CONCLUSION : Thiamine pyrophosphate prevented liver oxidative damage induced with desflurane and may be useful in prophylaxis of desflurane induced hepatotoxicity.


Assuntos
Anestésicos Inalatórios/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Isoflurano/análogos & derivados , Substâncias Protetoras/farmacologia , Tiamina Pirofosfato/uso terapêutico , Alanina Transaminase/efeitos dos fármacos , Alanina Transaminase/metabolismo , Animais , Aspartato Aminotransferases/efeitos dos fármacos , Aspartato Aminotransferases/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Desflurano , Glutationa/efeitos dos fármacos , Glutationa/metabolismo , Isoflurano/efeitos adversos , L-Lactato Desidrogenase/efeitos dos fármacos , L-Lactato Desidrogenase/metabolismo , Fígado/enzimologia , Fígado/patologia , Masculino , Malondialdeído/metabolismo , Modelos Animais , Óxido Nítrico/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Peroxidase/efeitos dos fármacos , Peroxidase/metabolismo , Ratos Wistar
5.
Acta cir. bras ; 31(3): 168-175, Mar. 2016. graf
Artigo em Inglês | LILACS | ID: lil-777089

RESUMO

ABSTRACT PURPOSE : To investigate the effects of thiamine pyrophosphate (TPP) against desflurane induced hepatotoxicity. METHODS : Thirty experimental animals were divided into groups as healthy (HG), desflurane control (DCG) , TPP and desflurane group (TDG). 20 mg/kg TPP was injected to intraperitoneally TDG. After one hour of TPP administration, desflurane was applied for two hours. After 24 hours, liver tissues of the animals killed with decapitation were removed. The oxidant/antioxidant levels and ALT, AST and LDH activities were measured. The histopathological examinations were performed in the liver tissues for all rats. RESULTS : Notwithstanding the levels of oxidants and liver enzymes were significantly increased (p<0.0001), antioxidant levels were significantly decreased in DCG (p<0.0001). On contrary to the antioxidant parameters were increased (p<0.05) the oxidant parameters and liver enzymes were decreased in TDG (p<0.0001). Whereas multiple prominent, congestion, hemorrhage and dilatation were observed in sinusoids and lymphocyte-rich inflammation results in the centrilobular and portal areas of liver tissue in DCG, these findings were observed less frequently in TDG. CONCLUSİON : Thiamine pyrophosphate prevented liver oxidative damage induced with desflurane and may be useful in prophylaxis of desflurane induced hepatotoxicity.


Assuntos
Animais , Masculino , Tiamina Pirofosfato/uso terapêutico , Anestésicos Inalatórios/efeitos adversos , Substâncias Protetoras/farmacologia , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Isoflurano/análogos & derivados , Aspartato Aminotransferases/efeitos dos fármacos , Aspartato Aminotransferases/metabolismo , Ratos Wistar , Peroxidase/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Alanina Transaminase/efeitos dos fármacos , Alanina Transaminase/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Glutationa/efeitos dos fármacos , Glutationa/metabolismo , Isoflurano , L-Lactato Desidrogenase/efeitos dos fármacos , L-Lactato Desidrogenase/metabolismo , Fígado/enzimologia , Fígado/patologia , Malondialdeído/metabolismo , Óxido Nítrico/metabolismo
6.
Basic Clin Pharmacol Toxicol ; 118(1): 70-6, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26432613

RESUMO

The aim of this study was to investigate whether thiamine pyrophosphate (TPP) has biochemical and histological preventive effects on oxidative liver damage induced by paracetamol (APAP). Rats were divided into the following groups: healthy control (HG), APAP (AG, 1500 mg/kg, orally), thiamine pyrophosphate (TPPG, 100 mg/kg, intraperitoneally), APAP+NAC (ANAC, 100 mg/kg, intraperitoneally), APAP+TPP (ATPG) and APAP+NAC+TPP (ANTG). Oxidant, antioxidant parameters, liver function tests and histological assessment were performed between groups. Malondialdehyde levels in the AG, HG, TPPG, ANAC, ATPG and ANTG groups were 0.470 ± 0.210, 0.213 ± 0.004, 0.194 ± 0.001, 0.197 ± 0.06, 0.199 ± 0.008 and 0.173 ± 0.010 µmol/g protein, respectively. Total glutathione levels were 7.787 ± 0.395, 14.925 ± 0.932, 13.200 ± 0.984, 13.162 ± 0.486, 13.287 ± 0.787 and 13.500 ± 0.891 µm/g protein, respectively. In the AG group, marked liver damage occurred with the elevation of liver function tests and oxidative stress markers, such as malondialdehyde, myeloperoxidase and nitric oxide (p < 0.05). Biochemical results were congruent with the histological changes of oxidative damage. Compared to the AG group (p < 0.05), TPP significantly reduced oxidant parameter levels in the ATPG group and simultaneously increased the antioxidant parameter levels of catalase and glutathione. The histological changes were improved to almost normal hepatic structure. Moreover, TPP had nearly the same hepatoprotective effect as NAC, and there was statistically no additional benefit with NAC co-treatment. There was no statistically significant difference (p > 0.05) among the ANAC, ANTG and ATPG groups in terms of oxidant/antioxidant levels. TPP proved to be as efficacious as standard therapy and may be beneficial in APAP-induced hepatotoxicity.


Assuntos
Acetaminofen/toxicidade , Antioxidantes/uso terapêutico , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Fígado/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Tiamina Pirofosfato/uso terapêutico , Acetilcisteína/administração & dosagem , Acetilcisteína/uso terapêutico , Animais , Antioxidantes/administração & dosagem , Catalase/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/patologia , Quimioterapia Combinada , Feminino , Glutationa/metabolismo , Fígado/metabolismo , Fígado/patologia , Testes de Função Hepática , Malondialdeído/metabolismo , Óxido Nítrico/metabolismo , Peroxidase/metabolismo , Ratos Wistar , Tiamina Pirofosfato/administração & dosagem
7.
Cutan Ocul Toxicol ; 35(3): 222-7, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26339826

RESUMO

CONTEXT: Ethambutol-induced retinal oxidative damage in patients with tuberculosis is still not being adequately treated. The protective effect of thiamine pyrophosphate against oxidative damage in some tissues has been reported, but no information on the protective effects of thiamine pyrophosphate against ethambutol-induced oxidative retinal damage has been found in the medical literature. OBJECTIVE: The objective is to investigate whether thiamine pyrophosphate has a protective effect against oxidative retinal damage in rats induced by ethambutol. MATERIALS AND METHODS: Experimental animals divided into four groups (n = 10): the healthy group (HG), the ethambutol control group (EMB), thiamine + ethambutol group (Thi-EMB) and thiamine pyrophosphate + ethambutol group (TPP-EMB). The rats in the TPP-EMB and Thi-EMB groups were administered thiamine pyrophosphate and thiamine, respectively, at doses of 20 mg/kg intraperitoneally. Distilled water was administered intraperitoneally to the HG and the EMB groups as a solvent in the same volumes. One hour after drug injection, 30 mg/kg ethambutol was administered via an oral gavage to the TPP-EMB, Thi-EMB and EMB groups. This procedure was repeated once a day for 90 days. At the end of this period, all rats were euthanized under high-dose thiopental sodium anesthesia, and biochemical and histopathological investigations of the retinal tissue were performed. RESULTS: Malondialdehyde (MDA) and DNA damage product 8-hydroxyguanine levels were significantly lower in the retinal tissue of TPP-EMB and HG groups compared to those of the Thi-EMB and EMB groups, and total glutathione (tGSH) was also found to be higher. In addition, severe retinal tissue vascularization, edema and loss of ganglion cells were observed in the Thi-EMB and EMB groups, whereas histopathological findings for the TPP-EMB group were observed to be close to normal. DISCUSSION AND CONCLUSION: These findings suggest that thiamine pyrophosphate protects retinal tissues from ethambutol-induced oxidative damage, and thiamine does not. This positive effect of thiamine pyrophosphate may be useful in the prevention of ocular toxicity that occurs during ethambutol use.


Assuntos
Antioxidantes/uso terapêutico , Antituberculosos/efeitos adversos , Etambutol/efeitos adversos , Oftalmopatias/induzido quimicamente , Oftalmopatias/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico , Animais , Antioxidantes/farmacologia , Dano ao DNA , Olho/efeitos dos fármacos , Olho/metabolismo , Olho/patologia , Oftalmopatias/metabolismo , Oftalmopatias/patologia , Glutationa/metabolismo , Guanina/análogos & derivados , Guanina/metabolismo , Masculino , Malondialdeído/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Ratos Wistar , Tiamina/farmacologia , Tiamina/uso terapêutico , Tiamina Pirofosfato/farmacologia
8.
Lik Sprava ; (5-6): 126-32, 2015.
Artigo em Russo | MEDLINE | ID: mdl-27089730

RESUMO

In the article the results of clinical researches of efficiency of preparation of Cocarnit are resulted for patients after endoprosthesis of large joints. It is routine that for patients, receiving preparation of Cocarnit after the operation period there was a decline in the amount of complaints of patients on the total somatical state. Preparation of Ccocarnit was positively estimated outside patients, meaningful by-reactions, serving reason of abolition of preparation, was not marked. At the reception preparation of Cocarnit greater part of investigational laboratory indexes (table of contents of glucose, ß-lipoproteines, total chondroitisulfates, TBC-productes (malonic dyaldehyde), activity of aspartataminotransferase, alkaline phosphatase and ß-glutamyltranspeptidase), the indexes of clinical blood test and leucocytar indexes during a supervision did not have reliable differences from such as the persons of the control group, that confirms good bearab leness of the indicated preparation. Application preparation of Cocarnit for patients in composition the chart of treatment of patients after endoprosthesis of large joints brought maintenance over of cholesterol to the decline, glycoproteins, TBC-products (malonic dyaldehyde), activity of alaninaminotransferase, that specifies on normalizing influence of the indicated preparation in relation to the basic types of exchange of matters.


Assuntos
Artroplastia de Quadril/reabilitação , Artroplastia do Joelho/reabilitação , Articulação do Quadril/efeitos dos fármacos , Articulação do Joelho/efeitos dos fármacos , Substâncias Protetoras/uso terapêutico , Trifosfato de Adenosina/uso terapêutico , Adulto , Idoso , Fosfatase Alcalina/sangue , Aspartato Aminotransferases/sangue , Glicemia/metabolismo , Sulfatos de Condroitina/sangue , Combinação de Medicamentos , Feminino , Articulação do Quadril/metabolismo , Articulação do Quadril/patologia , Articulação do Quadril/cirurgia , Humanos , Articulação do Joelho/metabolismo , Articulação do Joelho/patologia , Articulação do Joelho/cirurgia , Lipoproteínas LDL/sangue , Masculino , Malondialdeído/sangue , Pessoa de Meia-Idade , Niacinamida/uso terapêutico , Estresse Oxidativo/efeitos dos fármacos , Satisfação do Paciente , Qualidade de Vida , Tiamina Pirofosfato/uso terapêutico , Vitamina B 12/uso terapêutico , gama-Glutamiltransferase/sangue
9.
Lik Sprava ; (7-8): 95-8, 2015.
Artigo em Ucraniano | MEDLINE | ID: mdl-27491158
10.
Lik Sprava ; (7-8): 141-8, 2015.
Artigo em Russo | MEDLINE | ID: mdl-27491167

RESUMO

In clinical trial included 41 patient with clinic-instrumental dates, which said about myocardium dysfunction and system diseases of connecting fabric and displays of CCI I-III of functional class (FC). Including of complex metabolic drug Cocarnit in standard therapy of systemdiseases of connecting fabric was instrumental in more expressed clinical improvement of patientsclinical dates in 15 days of supervision: a weakness diminished on 66.67%, shortbreathing at the insignificant physical loading--on 23.81%, at the ordinary physical loading--on 47.62%, at the megascopic physical loading--on 19.05%, pain in area of heart--on 42.85%, there are interruptions in-process heart--on 28.57%, oedematousness of shins--on 57.14%, sense of numbness, burning, sensitiveness to cold of extremities--on 57.14%. Quantity of patients with III FC diminished on 5 (23.81%), in a control group--on 2 (10%). It implementation of test with the 6-minute walking more expressed increase of the overcame distance is set for the patients of basicgroup--on 15.46% as compared to a control group--on 7.01%. Cocarnit patients estimatedpositively; side effects with subsequent abolition of drug, were not. Laboratory indexes (AlAT, AsAT, bilirubin, kreatinine, haemoglobin) at the end of trial did not change considerably, that confirmed good bearableness of drug.


Assuntos
Angina Pectoris/tratamento farmacológico , Cardiomiopatias/tratamento farmacológico , Cardiotônicos/uso terapêutico , Tecido Conjuntivo/efeitos dos fármacos , Dispneia/tratamento farmacológico , Insuficiência Cardíaca/prevenção & controle , Hipestesia/tratamento farmacológico , Trifosfato de Adenosina/uso terapêutico , Adulto , Idoso , Alanina Transaminase/sangue , Angina Pectoris/sangue , Angina Pectoris/patologia , Angina Pectoris/fisiopatologia , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Cardiomiopatias/sangue , Cardiomiopatias/patologia , Cardiomiopatias/fisiopatologia , Estudos de Casos e Controles , Tecido Conjuntivo/patologia , Creatinina/sangue , Combinação de Medicamentos , Dispneia/sangue , Dispneia/patologia , Dispneia/fisiopatologia , Feminino , Glicina/uso terapêutico , Insuficiência Cardíaca/sangue , Insuficiência Cardíaca/patologia , Insuficiência Cardíaca/fisiopatologia , Hemoglobinas/metabolismo , Humanos , Hipestesia/sangue , Hipestesia/patologia , Hipestesia/fisiopatologia , Masculino , Pessoa de Meia-Idade , Miocárdio/metabolismo , Miocárdio/patologia , Niacinamida/uso terapêutico , Tiamina Pirofosfato/uso terapêutico , Vitamina B 12/uso terapêutico
11.
Acta ortop. mex ; 28(3): 168-172, may.-jun. 2014. ilus
Artigo em Espanhol | LILACS | ID: lil-725132

RESUMO

El pie diabético representa una de las complicaciones más comunes en pacientes que han tenido una larga evolución. La etiología se circunscribe a la neuropatía, infecciones e isquemia, que actuando en conjunto contribuyen a la secuencia de necrosis tisular, ulceración y gangrena. Lo difícil que resulta su tratamiento hace necesaria la búsqueda de opciones que colaboren en la resolución de esta problemática, que se centra en la hiperglucemia crónica como detonante. El pirofosfato de tiamina o cocarboxilasa realiza múltiples actividades metabólicas y no metabólicas que han sido consideradas importantes en la solución de las alteraciones del diabético por lo que en el presente trabajo se muestran los resultados al emplearlo en pacientes con pie diabético. En un período comprendido entre Enero de 1998 y Julio de 2012 se trataron 29 pacientes con pie diabético: 19 Wagner tipo III y 12 Wagner tipo IV. El manejo consistió en administrar antibióticos, procedimientos quirúrgicos parciales y pirofosfato de tiamina. Se logró el control del proceso infeccioso, la aparición de tejido de granulación y cicatrización de la lesión en un período comprendido entre 2 y 6 meses de acuerdo a la gravedad del problema. Por los datos clínicos y la evolución de los pacientes, se concluye que la administración del pirofosfato de tiamina permitió el control de las disfunciones metabólicas y no metabólicas que conducen a las complicaciones del diabético, por lo que se debe considerar una herramienta para el tratamiento de los diabéticos en general y para el rescate del pie diabético en particular.


Diabetic foot represents one of the most common complications in patients with a long standing disease. The etiology is neuropathy, infections and ischemia that together contribute to the sequence of tissue necrosis, ulceration and gangrene. Since treatment is very difficult, we must look for several options to solve these problems caused by chronic hyperglycemia. Thiamine pyrophosphate or carboxylase perform multiple metabolic and non-metabolic activities that are considered important in the resolution of diabetic impairments, therefore, this work shows the results when using it in patients with diabetic foot. 29 patients with diabetic foot were treated between January 1998 and July 2012: 19 Wagner type III and 12 Wagner type IV. Management was the administration of antibiotics, partial surgical procedures and thiamine pyrophosphate. The infectious process was controlled, the appearance of granulation tissue and scarring of the lesion in a period of 2 to 6 months depending on the severity of the problem. Given the clinical data and evolution of the patients, we conclude that the administration of thiamine pyrophosphate was able to control metabolic and non-metabolic dysfunctions that lead to complications in diabetic patients, therefore we must consider it a tool in the treatment of diabetic patients in general and for diabetic foot salvage in particular.


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pé Diabético/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico , Complexo Vitamínico B/uso terapêutico , Estudos Longitudinais
12.
J Pediatr ; 164(6): 1456-61, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24607240

RESUMO

OBJECTIVES: To compare blood thiamine concentrations, echocardiography findings, and plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in infants with clinically diagnosed beriberi and healthy matched controls, and to evaluate changes after thiamine treatment. STUDY DESIGN: Sixty-two Cambodian infants (20 cases and 42 controls), aged 2-47 weeks, were enrolled in this prospective study. Echocardiography and phlebotomy were performed at baseline and after thiamine treatment. RESULTS: Both cases and controls were thiamine-deficient, with median blood thiamine diphosphate (TDP) concentrations of 47.6 and 55.1 nmol/L, respectively (P = .23). All subjects had normal left ventricular ejection fraction. The median NT-proBNP concentration in cases (340 pg/mL [40.1 pmol/L]) was higher than previously reported normal ranges, but not statistically significantly different from that in controls (175 pg/mL [20.7 pmol/L]) (P = .10), and was not correlated with TDP concentration (P = .13). Two cases with the lowest baseline TDP concentrations (24 and 21 nmol/L) had right ventricular enlargement and elevated NT-proBNP levels that improved dramatically by 48 hours after thiamine administration. CONCLUSION: Only a minority of thiamine-deficient Cambodian infants demonstrate abnormal echocardiography findings. Thiamine deficiency produces echocardiographic evidence of right ventricular dysfunction, but this evidence is not apparent until deficiency is severe. NT-proBNP concentrations are mildly elevated in sick infants with normal echocardiography findings, indicating possible physiological changes not yet associated with echocardiographic abnormalities.


Assuntos
Peptídeo Natriurético Encefálico/sangue , Fragmentos de Peptídeos/sangue , Deficiência de Tiamina/complicações , Tiamina Pirofosfato/uso terapêutico , Disfunção Ventricular Esquerda/etiologia , Povo Asiático/estatística & dados numéricos , Beriberi/sangue , Beriberi/complicações , Beriberi/etnologia , Biomarcadores/metabolismo , Estudos de Casos e Controles , Ecocardiografia Doppler/métodos , Feminino , Seguimentos , Testes de Função Cardíaca , Humanos , Lactente , Recém-Nascido , Masculino , Valores de Referência , Medição de Risco , Índice de Gravidade de Doença , Deficiência de Tiamina/sangue , Deficiência de Tiamina/tratamento farmacológico , Deficiência de Tiamina/etnologia , Tiamina Pirofosfato/sangue , Resultado do Tratamento , Disfunção Ventricular Esquerda/diagnóstico , Disfunção Ventricular Esquerda/etnologia
13.
Epilepsy Res ; 108(3): 405-10, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24434003

RESUMO

This study examines the effect of thiamine (TH) and thiamine pyrophosphate (TPP) on epileptic episode model induced in rats with caffeine. Animals were divided into groups and given TH or TPP at doses of 10, 30 or 50mg/kg intraperitoneally. Subsequently, all animal groups were injected intraperitoneally with caffeine at a dose of 300mg/kg. Time of onset of epileptic episode was recorded, and the latent period was calculated in seconds. At the end of the experiment, tGSH and MDA levels and SOD and MPO enzyme activities in extracted brain tissues were measured. Latent period duration in rats in the control group was 134±3.2s, compared to 144±13.9, 147±14.5 and 169±15.1s, respectively, in the TH10, TH30 and TH50 groups and 184±8.54, 197±9.1, 225±8.37s, respectively, in the TPP10, TPP30 and TPP50 groups. Latent period duration was 236±6.7 in the diazepam group. Oxidant products were significantly lower in the TPP10, TPP30, TPP50 and diazepam groups compared to the control group (P<0.05), while SOD activity and tGSH levels were significantly higher (P<0.05). There was no significant difference between the TH10, TH30, TH50 groups and the control group in terms of oxidant and antioxidant levels (P>0.05). In conclusions, TPP, especially at a dose of 50mg/kg, significantly prolonged the latent period from administration of caffeine to time of episode and prevented oxidative damage.


Assuntos
Cafeína/toxicidade , Estimulantes do Sistema Nervoso Central/toxicidade , Epilepsia/induzido quimicamente , Epilepsia/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico , Tiamina/uso terapêutico , Complexo Vitamínico B/uso terapêutico , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Epilepsia/patologia , Glutationa/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Malondialdeído/metabolismo , Ratos , Ratos Wistar , Superóxido Dismutase/metabolismo
14.
Hum Exp Toxicol ; 33(1): 14-21, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23632005

RESUMO

This study investigated the effects of thiamine pyrophosphate (TPP) at dosages of 10 and 20 mg/kg on oxidative stress induced in rat brain tissue with cisplatin and compared this with thiamine. Cisplatin neurotoxicity represents one of the main restrictions on the drug being given in effective doses. Oxidative stress is considered responsible for cisplatin toxicity. Our results showed that cisplatin increased the levels of oxidant parameters such as lipid peroxidation (thio barbituric acid reactive substance (TBARS)) and myeloperoxidase (MPO) in brain tissue and suppressed the effects of antioxidants such as total glutathione (GSH) and superoxide dismutase (SOD). TPP, especially at a dosage of 20 mg/kg, significantly reduced TBARS and MPO levels that increase with cisplatin administration compared with the thiamine group, while TPP significantly increases GSH and SOD levels. In addition, the level of 8-Gua (guanine), a product of DNA damage, was 1.7 ± 0.12 8-hydroxyl guanine (8-OH Gua)/105 Gua in brain tissue in the control group receiving cisplatin, compared with 0.97 ± 0.03 8-OH Gua/105 Gua in the thiamine pyrophosphate (20 mg/kg) group and 1.55 ± 0.11 8-OH Gua/105 Gua in the thiamine (20 mg/kg) group. These results show that thiamine pyrophosphate significantly prevents oxidative damage induced by cisplatin in brain tissue, while the protective effect of thiamine is insignificant.


Assuntos
Antineoplásicos/efeitos adversos , Cérebro/metabolismo , Cisplatino/efeitos adversos , Fármacos Neuroprotetores/uso terapêutico , Síndromes Neurotóxicas/prevenção & controle , Estresse Oxidativo , Tiamina Pirofosfato/uso terapêutico , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/antagonistas & inibidores , Cérebro/efeitos dos fármacos , Cérebro/enzimologia , Cisplatino/administração & dosagem , Cisplatino/antagonistas & inibidores , Dano ao DNA , Injeções Intraperitoneais , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Proteínas do Tecido Nervoso/agonistas , Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/enzimologia , Neurônios/metabolismo , Fármacos Neuroprotetores/administração & dosagem , Síndromes Neurotóxicas/metabolismo , Oxirredutases/antagonistas & inibidores , Oxirredutases/química , Oxirredutases/metabolismo , Distribuição Aleatória , Ratos , Ratos Wistar , Tiamina/administração & dosagem , Tiamina/uso terapêutico , Tiamina Pirofosfato/administração & dosagem , Complexo Vitamínico B/administração & dosagem , Complexo Vitamínico B/uso terapêutico
15.
Acta Ortop Mex ; 28(3): 168-72, 2014.
Artigo em Espanhol | MEDLINE | ID: mdl-26021112

RESUMO

Diabetic foot represents one of the most common complications in patients with a long standing disease. The etiology is neuropathy, infections and ischemia that together contribute to the sequence of tissue necrosis, ulceration and gangrene. Since treatment is very difficult, we must look for several options to solve these problems caused by chronic hyperglycemia. Thiamine pyrophosphate or carboxylase perform multiple metabolic and non-metabolic activities that are considered important in the resolution of diabetic impairments, therefore, this work shows the results when using it in patients with diabetic foot. 29 patients with diabetic foot were treated between January 1998 and July 2012: 19 Wagner type III and 12 Wagner type IV. Management was the administration of antibiotics, partial surgical procedures and thiamine pyrophosphate. The infectious process was controlled, the appearance of granulation tissue and scarring of the lesion in a period of 2 to 6 months depending on the severity of the problem. Given the clinical data and evolution of the patients, we conclude that the administration of thiamine pyrophosphate was able to control metabolic and non-metabolic dysfunctions that lead to complications in diabetic patients, therefore we must consider it a tool in the treatment of diabetic patients in general and for diabetic foot salvage in particular.


Assuntos
Pé Diabético/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico , Complexo Vitamínico B/uso terapêutico , Adulto , Idoso , Feminino , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade
16.
ScientificWorldJournal ; 2013: 182694, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24163613

RESUMO

OBJECTIVE: The aim of this study was to evaluate the effectiveness of thiamine pyrophosphate against cisplatin-induced ototoxicity in guinea pigs. MATERIALS AND METHODS: Healthy guinea pigs (n = 18) were randomly divided into three groups. Group 1 (n = 6) received an intraperitoneal injection of saline solution and cisplatin for 7 days, group 2 (n = 6) received an intraperitoneal injection of thiamine pyrophosphate and cisplatin for 7 days, and group 3 (n = 6) received only intraperitoneal injection of saline for 7 days. The animals in all groups were sacrificed under anesthesia, and their cochleas were harvested for morphological and biochemical observations. RESULTS: In group 1, receiving only cisplatin, cochlear glutathione concentrations, superoxide dismutase, and glutathione peroxidase activities significantly decreased (P < 0.05) and malondialdehyde concentrations significantly increased (P < 0.05) compared to the control group. In group 2, receiving thiamine pyrophosphate and cisplatin, the concentrations of enzymes were near those of the control group. Microscopic examination showed that outer hair cells, spiral ganglion cells, and stria vascularis were preserved in group 2. CONCLUSION: Systemic administration of thiamine pyrophosphate yielded statistically significant protection to the cochlea of guinea pigs from cisplatin toxicity. Further experimental animal studies are essential to determine the appropriate indications of thiamine pyrophosphate before clinical use.


Assuntos
Cisplatino/toxicidade , Tiamina Pirofosfato/uso terapêutico , Animais , Antioxidantes/metabolismo , Cóclea/efeitos dos fármacos , Cóclea/metabolismo , Glutationa/metabolismo , Cobaias , Masculino , Modelos Animais
17.
Indian J Pharmacol ; 45(4): 339-43, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24014907

RESUMO

OBJECTIVES: The biochemical effects of thiamine pyrophosphate on ischemia-reperfusion (IR) induced oxidative damage and DNA mutation in rat kidney tissue were investigated, and compared to thiamine. MATERIALS AND METHODS: Rats were divided into four groups: renal ischemia-reperfusion (RIR); thiamine pyrophosphate + RIR (TPRIR); thiamine + RIR (TRIR); and sham group (SG). RESULTS: The results of biochemical experiments have shown that malondialdehyde (MDA) levels in rat kidney tissue after TRIR and TPRIR treatment were 7.2 ± 0.5 (P > 0.05) and 3.3 ± 0.3 (P < 0.0001) µmol/g protein, respectively. The MDA levels in the SG rat kidney tissue and in RIR group were 3.6 ± 0.2 (P < 0.0001) and 7.6 ± 0.6 µmol/g protein, respectively. Total glutathione (tGSH) levels in TRIR, TPRIR, SG, and RIR animal groups were 2.2 ± 0.3 (P > 0.05), 5.8 ± 0.4 (P < 0.0001), 6.2 ± 0.2 (P < 0.0001), and 1.7 ± 0.2 nmol/g protein, respectively. In the TRIR, TPRIR, SG, and RIR animal groups; 8-hydroxyguanine (8-OHGua)/Gua levels, which indicate mutagenic DNA, were 1.75 ± 0.12 (P > 0.05), 0.93 ± 0.1 (P < 0.0001), 0.85 ± 0.08 (P < 0.0001), and 1.93 ± 0.24 pmol/L, respectively. CONCLUSIONS: It has been shown that thiamine pyrophosphate prevents increase in mutagenic DNA in IR induced oxidative damage, whereas thiamine does not have this effect.


Assuntos
Rim/efeitos dos fármacos , Substâncias Protetoras/uso terapêutico , Traumatismo por Reperfusão/tratamento farmacológico , Tiamina Pirofosfato/uso terapêutico , Animais , Dano ao DNA , Glutationa/metabolismo , Guanina/análogos & derivados , Guanina/metabolismo , Rim/metabolismo , Masculino , Malondialdeído/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Substâncias Protetoras/farmacologia , Ratos , Ratos Wistar , Traumatismo por Reperfusão/metabolismo , Tiamina Pirofosfato/farmacologia
18.
Eur J Obstet Gynecol Reprod Biol ; 170(2): 521-5, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23916585

RESUMO

OBJECTIVE: To investigate whether thiamine pyrophosphate can prevent infertility developing in rats undergoing unilateral ovariectomy and with ischemia reperfusion induced in the contralateral ovary. Biochemical examinations of the ovaries were also performed. STUDY DESIGN: Rats were divided into two main groups of three subgroups each. An ischemia reperfusion model was established in the first main group, while surgical unilateral ovariectomy was performed in the second. Thiamine pyrophosphate and melatonin were administered to the subgroups. No additional procedure was performed in the control groups. The rats were then left in laboratory environments and their fertility levels were determined. Malondialdehyde, total glutathione and DNA damage products were measured in those rats from which ovarian tissue was collected. RESULTS: The results showed that thiamine pyrophosphate prevented ischemia/reperfusion injury-related infertility, but melatonin did not provide adequate prevention. However, reproduction in healthy animals receiving melatonin began earlier compared to those receiving thiamine pyrophosphate. Melatonin suppressed oxidative stress caused by ischemia/reperfusion in ovarian tissue significantly better than did thiamine pyrophosphate. CONCLUSIONS: We think that different mechanisms, in addition to antioxidant activity, are involved in the prevention of reperfusion-associated infertility after ischemia.


Assuntos
Infertilidade Feminina/prevenção & controle , Doenças Ovarianas/tratamento farmacológico , Traumatismo por Reperfusão/prevenção & controle , Tiamina Pirofosfato/uso terapêutico , Complexo Vitamínico B/uso terapêutico , Animais , Antioxidantes/uso terapêutico , Modelos Animais de Doenças , Feminino , Infertilidade Feminina/etiologia , Melatonina/uso terapêutico , Doenças Ovarianas/complicações , Ovariectomia , Distribuição Aleatória , Ratos , Ratos Wistar , Traumatismo por Reperfusão/complicações
19.
Arch Pharm Res ; 36(9): 1133-9, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23760618

RESUMO

In this study, the biochemical and histopathological effects of thiamine and thiamine pyrophosphate on ischemia-reperfusion induced oxidative damage in rat ovarian tissue were investigated. Animals were divided into four groups of six rat each, ovarian ischemia-reperfusion (IR), 25 mg/kg thiamine + ovarian ischemia-reperfusion (TIR), 25 mg/kg thiamine pyrophosphate + ovarian ischemia-reperfusion (TPIR) and Sham group (SG). The results of the biochemical experiments have shown that the rat ovarian tissue with thiamine treatment, the level of MDA, GSH and the 8-hydroxyguanine are almost the same as the IR group; while in the group with thiamine pyrophosphate treatment, the level of MDA, GSH and the 8-hydroxyguanine are almost the same as the SG. Ovarian tissue of rats in the IR group were congested and dilated vessels, edema, hemorrhage, necrotic and apoptotic cells. In this group, the migration and the adhesion of the polymorphonuclear leucocytes to the endothelium were observed. Both ovaries in TPIR group, there was no difference according to the SG. Histopathology of ovarian tissues in the TIR group was almost the same with the IR group. Our results indicate that thiamine pyrophosphate significantly prevents the ischemia-reperfusion induced oxidative damage in ovarian tissue, whereas thiamine has no effect. In conclusion, we have found that thiamine pyrophosphate prevents oxidative damage due to ischemia-reperfusion injury, whereas thiamine does not have this effect. Furthermore, we have confirmed that the results of our biochemical analyses are in concordance with the histopathological findings.


Assuntos
Antioxidantes/uso terapêutico , Dano ao DNA/efeitos dos fármacos , Isquemia/tratamento farmacológico , Ovário/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Traumatismo por Reperfusão/prevenção & controle , Tiamina Pirofosfato/uso terapêutico , Animais , Antioxidantes/administração & dosagem , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/imunologia , Endotélio Vascular/patologia , Feminino , Glutationa/metabolismo , Injeções Intraperitoneais , Isquemia/metabolismo , Isquemia/patologia , Isquemia/fisiopatologia , Peroxidação de Lipídeos/efeitos dos fármacos , Malondialdeído/metabolismo , Infiltração de Neutrófilos/efeitos dos fármacos , Ovário/irrigação sanguínea , Ovário/metabolismo , Ovário/patologia , Oxirredução , Distribuição Aleatória , Ratos , Ratos Wistar , Traumatismo por Reperfusão/etiologia , Tiamina/administração & dosagem , Tiamina/uso terapêutico , Tiamina Pirofosfato/administração & dosagem
20.
Lik Sprava ; (3-4): 75-81, 2012.
Artigo em Ucraniano | MEDLINE | ID: mdl-23356142

RESUMO

Left ventricular diastolic dysfunction in patients with diabetes is formed in the absence of atherosclerotic changes as a consequence of diabetic cardiac autonomic neuropathy in the early stages of diabetes. Progression of autonomic cardiac neuropathy in cardio-vascular type is associated with the violation of energy supply of cells, protein synthesis, electrolyte exchange, the exchange of trace elements, oxidation reduction processes, oxygen-transport function of blood, so that metabolic therapy is carried out to optimize the processes of formation and energy costs. The drug cocarnit activates processes of aerobic oxidation of glucose, as well as providing regulatory influence on the oxidation of fatty acids. Applying of cocarnit in complex therapy in patients with diabetic cardiac autonomic neuropathy found improvement of left ventricular diastolic function, and positive dynamics in the efferent activity balance of the sympathetic and parasympathetic control of heart rate variability, which provides the regression of clinical symptoms.


Assuntos
Cardiomiopatias/tratamento farmacológico , Cardiotônicos/uso terapêutico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Neuropatias Diabéticas/tratamento farmacológico , Disfunção Ventricular Esquerda/tratamento farmacológico , Trifosfato de Adenosina/farmacologia , Trifosfato de Adenosina/uso terapêutico , Adolescente , Adulto , Sistema Nervoso Autônomo/efeitos dos fármacos , Sistema Nervoso Autônomo/metabolismo , Cardiomiopatias/complicações , Cardiomiopatias/metabolismo , Cardiotônicos/farmacologia , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/metabolismo , Neuropatias Diabéticas/complicações , Neuropatias Diabéticas/metabolismo , Combinação de Medicamentos , Ácidos Graxos/metabolismo , Feminino , Glucose/metabolismo , Coração/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Niacinamida/farmacologia , Niacinamida/uso terapêutico , Oxirredução , Tiamina Pirofosfato/farmacologia , Tiamina Pirofosfato/uso terapêutico , Disfunção Ventricular Esquerda/complicações , Disfunção Ventricular Esquerda/metabolismo , Função Ventricular Esquerda/efeitos dos fármacos , Função Ventricular Esquerda/fisiologia , Vitamina B 12/farmacologia , Vitamina B 12/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...